id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-3316-0008,FDA,FDA-2015-E-3316,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-07-29T04:00:00Z,2018,7,2018-07-29T04:00:00Z,,2018-07-29T04:35:50Z,,0,0,09000064835733c3
FDA-2015-E-3316-0006,FDA,FDA-2015-E-3316,Determination of Regulatory Review Periods for Purposes of Patent Extension: ADVANTAME,Notice,Determinations,2017-11-30T05:00:00Z,2017,11,2017-11-30T05:00:00Z,2018-01-30T04:59:59Z,2017-11-30T15:57:22Z,2017-25780,0,0,0900006482cc09cd
FDA-2015-E-3316-0007,FDA,FDA-2015-E-3316,Determination of Regulatory Review Periods for Purposes of Patent Extension: ADVANTAME,Notice,Determinations,2017-11-30T05:00:00Z,2017,11,2017-11-30T05:00:00Z,2018-01-30T04:59:59Z,2017-11-30T15:59:10Z,2017-25780,0,0,0900006482cc2a5c
FDA-2015-E-3316-0005,FDA,FDA-2015-E-3316,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-07-12T04:00:00Z,2017,7,2017-07-12T04:00:00Z,,2017-07-12T20:51:13Z,,0,0,09000064829144e7
FDA-2015-E-3316-0004,FDA,FDA-2015-E-3316,Letter from U.S. Patent and Trademark Office to FDA,Other,Letter(s),2017-06-01T04:00:00Z,2017,6,2017-06-01T04:00:00Z,,2017-06-01T15:16:32Z,,0,0,090000648267731b
FDA-2015-E-3316-0003,FDA,FDA-2015-E-3316,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-02T05:00:00Z,2015,11,2015-11-02T05:00:00Z,,2015-11-02T15:29:52Z,,0,0,0900006481cfe1a8
FDA-2015-E-3316-0002,FDA,FDA-2015-E-3316,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2015-09-10T04:00:00Z,2015,9,2015-09-10T04:00:00Z,,2015-09-10T17:16:30Z,,0,0,0900006481c66014
FDA-2015-E-3316-0001,FDA,FDA-2015-E-3316,"Patent Extension Application from Oblon Spivak, McClelland, Maier & Neustadt, LLP (on behalf of  Ajinomoto Co., Inc.)",Other,Application,2015-09-10T04:00:00Z,2015,9,2015-09-10T04:00:00Z,,2015-09-10T19:18:48Z,,0,0,0900006481c66016